Fenorasboston 300

Fenorasboston 300

201912-0047 • 2898 Views • 5 blisters x 10 hard capsules
COMPOSITION

Each hard capsule contains:

Active ingredients:

Fenofibrate 300 mg

 

Treatment of disorders of lipoproteinanemia in types IIa, IIb, III, IV and V, in combination with diet.

POSOLOGY, METHOD OF ADMINISTRATION

Method of administration: Combine treatment with a fat-lowering diet. The drug should be taken with meals to maximize bioavailability.

Posology: 

Adults: Take 1 capsule/day; take 1 time with the main meal.

The initial dose of fenofibrate is usually 200 mg/day (once or twice); if total cholesterolemia is still higher than 4 g/l, the dose can be increased to 300 mg/day. The initial dose should be maintained until cholesterolemia returns to normal after the daily dose can be slightly reduced. Cholesterolemia must be checked every 3 months; if blood lipid parameters increase again, the dose must be increased to 300mg/day.

 

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients of the drug.

Patients with renal impairment

Severe liver dysfunction.

It's not suitable for children.

Pregnancy and lactation

 

WARNINGS AND PRECAUTIONS

- It is essential to assess the patient's liver and kidney function before treatment with fenofibrate.

- When initiating fibrate in a patient taking anticoagulants, the anticoagulant dose should be reduced to only one-third of the original dose and adjusted if necessary—more frequent monitoring of blood prothrombin levels. Adjust anticoagulant dose during use and 8 days after stopping fibrate.

- If after 3 - 6 months of treatment with the maximum recommended daily dose, lipidaemias do not decrease, an additional or alternative treatment must be considered.

- Do not combine fenofibrate with drugs that have hepatotoxic effects.

- Complications of cholelithiasis are more likely to occur in people with cholestatic cirrhosis or gallstones.

- Fenofibrate is not recommended for children below 18 years of age, as the safety and effectiveness were not established.

- It is recommended that transaminase levels be monitored every 3 months during the first 12 months of treatment. Fenofibrate therapy should be discontinued if SGPT (ALT) > 100 UI.

SHELF-LIFE

36 months from the date of manufacture. Do not use the products over the expiry date.

 

 

 

 5 blisters x 10 hard capsules

Your comment

Similar products

Crestin Boston 10
Box of 05 blisters x 14 film-coated tablets
Contact Us
Avasboston 20
Box of 5 blisters x 10 film-coated tablets
Contact Us
Avasboston 10
Box of 5 blisters x 10 tablets
Contact Us
19001910
Confirm information
Please confirm that you are a pharmacist, doctor, medical specialist,... and want to learn about the product. The information described here is only to help readers better understand the product, not for advertising or treatment purposes.